Analysts Expect BioXcel Therapeutics, Inc. (NASDAQ:BTAI) to Post -$1.27 EPS

Wall Street brokerages forecast that BioXcel Therapeutics, Inc. (NASDAQ:BTAIGet Rating) will report earnings per share of ($1.27) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for BioXcel Therapeutics’ earnings. The highest EPS estimate is ($0.95) and the lowest is ($1.73). BioXcel Therapeutics posted earnings per share of ($1.11) in the same quarter last year, which would indicate a negative year over year growth rate of 14.4%. The company is scheduled to report its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that BioXcel Therapeutics will report full-year earnings of ($4.63) per share for the current financial year, with EPS estimates ranging from ($6.07) to ($2.61). For the next financial year, analysts forecast that the business will post earnings of ($3.95) per share, with EPS estimates ranging from ($8.05) to ($0.33). Zacks’ EPS calculations are an average based on a survey of research firms that follow BioXcel Therapeutics.

BioXcel Therapeutics (NASDAQ:BTAIGet Rating) last released its earnings results on Monday, May 9th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.21) by $0.09. During the same period in the prior year, the business posted ($1.08) EPS.

Several analysts have issued reports on BTAI shares. Canaccord Genuity Group dropped their price objective on BioXcel Therapeutics from $84.00 to $75.00 in a research note on Friday. UBS Group dropped their price objective on BioXcel Therapeutics from $88.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, February 16th. Truist Financial dropped their price objective on BioXcel Therapeutics from $125.00 to $71.00 in a research note on Tuesday. HC Wainwright upped their price objective on BioXcel Therapeutics from $130.00 to $134.00 and gave the company a “buy” rating in a research note on Thursday, April 14th. Finally, Bank of America upped their price objective on BioXcel Therapeutics from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, April 6th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $68.43.

NASDAQ:BTAI opened at $11.74 on Friday. The stock’s 50 day moving average price is $16.26 and its two-hundred day moving average price is $19.85. The firm has a market capitalization of $328.60 million, a price-to-earnings ratio of -2.85 and a beta of 1.31. BioXcel Therapeutics has a 12-month low of $9.08 and a 12-month high of $39.00.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Rockefeller Capital Management L.P. increased its stake in shares of BioXcel Therapeutics by 122.2% during the third quarter. Rockefeller Capital Management L.P. now owns 2,000 shares of the company’s stock worth $60,000 after purchasing an additional 1,100 shares during the period. Macquarie Group Ltd. increased its stake in shares of BioXcel Therapeutics by 136.1% during the third quarter. Macquarie Group Ltd. now owns 3,197 shares of the company’s stock worth $97,000 after purchasing an additional 1,843 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of BioXcel Therapeutics during the third quarter worth approximately $109,000. Ensign Peak Advisors Inc acquired a new stake in BioXcel Therapeutics during the fourth quarter worth approximately $110,000. Finally, Metropolitan Life Insurance Co NY grew its position in BioXcel Therapeutics by 22.9% during the third quarter. Metropolitan Life Insurance Co NY now owns 4,882 shares of the company’s stock worth $148,000 after buying an additional 909 shares in the last quarter. Institutional investors own 49.77% of the company’s stock.

About BioXcel Therapeutics (Get Rating)

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors.

See Also

Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.